Related Experiment Video
Updated: Jun 17, 2025

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
Published on: March 25, 2022
Management and outcomes of antithrombotic therapy in EUS-guided gallbladder drainage
Michael Makar1, Michael Yodice1, Matt Still1
1Department of Gastroenterology and Hepatology, Geisinger Medical Center, Danville, Pennsylvania, USA.
Insights
EUS-guided gallbladder drainage is safe for patients on antithrombotic therapy (ATT). Holding ATT for the procedure did not increase bleeding, thrombotic events, or mortality risks.
Area of Science:
- Gastroenterology
- Interventional Endoscopy
- Patient Safety
Background:
- EUS-guided gallbladder drainage (EUS-GBD) is an alternative treatment for gallbladder disease in high-risk patients.
- Patients undergoing EUS-GBD often have comorbidities requiring antithrombotic therapy (ATT).
Purpose of the Study:
- To evaluate the safety and outcomes of EUS-GBD in patients on ATT.
- To compare bleeding and thrombotic events in patients on ATT versus no ATT.
Main Methods:
- Retrospective study of 177 patients undergoing EUS-GBD (2018-2023).
- Compared outcomes between patients on ATT (held for procedure) and those not on ATT.
- Primary outcomes: bleeding within 48 hours and 30 days. Secondary outcomes: thrombotic events, length of stay, 30-day mortality.
Main Results:
- 118 of 177 patients were on ATT.
- No significant difference in bleeding rates within 48 hours (0.9% vs 0%) or 30 days (3.5% vs 0%) between groups.
- No significant differences in thrombotic events, length of stay, or 30-day mortality between groups.
Conclusions:
- EUS-GBD can be safely performed in patients requiring ATT.
- Appropriately holding ATT for EUS-GBD does not increase the risk of adverse events.
Background And Aims:
EUS-guided gallbladder drainage (EUS-GBD) is increasingly used for the management of gallbladder disease in patients at high risk for cholecystectomy. These patients often have underlying medical comorbidities requiring anticoagulation and/or antiplatelet therapy. We evaluated the safety, management, and outcomes of EUS-GBD in patients being treated with antithrombotic therapy (ATT).
Methods:
We performed a retrospective study of patients undergoing EUS-GBD between 2018 and 2023 within Geisinger Health System. Outcomes were analyzed between patients previously on ATT but held for the procedure compared with no ATT. Primary outcomes were bleeding within 48 hours and 30 days. Secondary outcomes were risk of thrombotic events, length of stay, and 30-day mortality.
Results:
Of 177 patients undergoing EUS-GBD, 118 patients were on ATT. No statistical difference was found for EUS-GBD-related bleeding for patients on ATT compared with no ATT within 48 hours (.9% vs 0%, P > .999) or within 30 days (3.5% vs 0%, P = .302). Overall, 5 patients (2.9%) had bleeding related to the EUS-GBD procedure. There was no difference between the groups for secondary outcomes: thrombotic events (2.5% vs 3.4%), length of stay (7 days vs 5 days), and 30-day mortality (11% vs 10.2%).
Conclusions:
Patients undergoing EUS-GBD who require ATT did not have any immediate or delayed increased risk of bleeding, thrombotic events, length of stay, or mortality when the medication was appropriately held.
Related Concept Videos
Endoscopic Procedures V: ERCP
Patient...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Acute Pancreatitis II: Clinical Manifestations and Management
Endoscopic Procedures I: Esophagogastroduodenoscopy
During an EGD, the endoscope can be used to:
Chronic Pancreatitis II: Collaborative Care
Assessment:
